Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234542 | 0.95 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTEPHX2L3MBTL1 | |
| SCHEMBL17885935 | 0.94 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTFAAHLPAR1 | |
| SCHEMBL19934110 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDHTTFAAHLPAR1 | |
| SCHEMBL19732507 | 0.90 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDHTTFAAHLPAR1 | |
| SCHEMBL20008742 | 0.90 | SMN1; SMN2 (0.48) | SMN1; SMN2HPGDHTTKMT2AL3MBTL1 | |
| SCHEMBL20365824 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDHTTKMT2AL3MBTL1 | |
| SCHEMBL12369355 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTFAAHKMT2A | |
| SCHEMBL4964608 | 0.88 | HPGD (0.45) | SMN1; SMN2HPGDHTTFAAHLPAR1 | |
| SCHEMBL21767237 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTKMT2AL3MBTL1 | |
| SCHEMBL17773347 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | SMN1; SMN2 2230/4885HPGD 3738/4885HTT 1559/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | SMN1; SMN2 2230/4885HPGD 3738/4885HTT 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.